Abstract—
Most xenobiotics undergo metabolic conversions in the human body. The biological activity, toxicity, and other properties of such metabolites may significantly differ from those of the parent compounds. Not only xenobiotics and their final metabolites produced in large quantities, but the intermediates and final metabolites formed in trace amounts, can cause undesirable effects. We have developed a freely available web application MetaTox (http://www.way2drug.com/mg/) for integral assessment of xenobiotics toxicity taking into account their metabolism in humans. The generation of the metabolite structures is based on the reaction fragments. The probability estimation of the certain reaction and the probability estimation of the atoms, which are changed during biotransformation, are used for generation of the xenobiotic metabolism pathways. The MetaTox web application assesses metabolism of compounds in humans and evaluates their acute toxicity, specific (cardiotoxicity, hepatotoxicity, nephrotoxicity), and chronic toxicity (carcinogenicity, teratogenicity, mutagenicity, effects on the reproductive system).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Testa, B. and Jenner, P., in Drug Metabolism: Chemical And Biochemical Aspects, Oelschläger, H., Ed., New York: Marcel Dekker Inc., 1976.
Benedetti, M.S., Whomsley, R., Poggesi, I., Cawello, W., Mathy, F.X., Delporte, M.L., Papeleu, P., and Watelet, J.B., Drug Metab. Rev., 2009, vol. 41, no. 3, pp. 344–390. https://doi.org/10.1080/10837450902891295
Liu, W., Shi, J., Zhu, L., Dong, L., Luo, F., Zhao, M., Wang, Y., Hu, M., Lu, L., and Liu, Z., Drug Des. Devel. Ther., 2015, vol. 9, pp. 5771–5783. https://doi.org/10.2147/DDDT.S92276
Li, X., Kamenecka, T.M., and Cameron, M.D., Drug Metab. Dispos., 2010, vol. 38, no. 7, pp. 1238–1245. https://doi.org/10.1124/dmd.109.030361
van Eij, S., Zh, Z., Cupit, J., Gierula, M., Götz, C., Fritsche, E., and Edwards, R.J., PLoS One, 2012, vol. 7, no. 7, e41721. https://doi.org/10.1371/journal.pone.0041721
FDA, Safety Testing of Drug Metabolites Guidance for Industry (2016) URL: https://www.fda.gov/downloads/Drugs/…/Guidances/ucm079266.pdf.
Bezhentsev, V.M., Tarasova, O.A., Dmitriev, A.V., Rudik, A.V., Lagunin, A.A., Filimonov, D.A., and Poroikov, V.V., Russ. Chem. Rev., 2016, vol. 85, no. 8, pp. 854–879. https://doi.org/10.1070/RCR4614
Kirchmair, J., Williamson, M.J., Tyzack, J.D., Tan, L., Bond, P.J., Bender, A., and Glen, R.C., J. Chem. Inf. Model., 2012, vol. 52, no. 3, pp. 617–648. https://doi.org/10.1021/ci200542m
Singh, S.B., Shen, L.Q., Walker, M.J., and Sheridan, R.P., J. Med. Chem., 2003, vol. 46, no. 8, pp. 1330–1336.
Kirchmair, J., Göller, A.H., Lang, D., Kunze, J., Testa, B., Wilson, I.D., Glen, R.C., and Schneider, G., Nat. Rev. Drug Discov., 2015, vol. 14, no. 6, pp. 387–404. https://doi.org/10.1038/nrd4581
Wang, B., Yang, L.-P., Zhang, X.-Z., Huang, S.-Q., Bartlam, M., and Zhou, S.-F., Drug Metab. Rev., 2009, vol. 41, no. 4, pp. 573–643. https://doi.org/10.1080/03602530903118729
Sliwoski, G., Kothiwale, S., Meiler, J., and Lowe, E.W., Pharmacol. Rev., 2014, vol. 66, no. 1, pp. 334–395. https://doi.org/10.1124/pr.112.007336
Ivanov, S.M., Lagunin, A.A., and Poroikov, V.V., Drug Discov. Today, 2016, vol. 21, no. 1, pp. 58–71. https://doi.org/10.1016/j.drudis.2015.07.018
Rudik, A.V., Bezhentsev, V.M., Dmitriev, A.V., Druzhilovskiy, D.S., Lagunin, A.A., Filimonov, D.A., and Poroikov, V.V., J. Chem. Inf. Model., 2017, vol. 57, no. 4, pp. 638–642. https://doi.org/10.1021/acs.jcim.6b00662
Rudik, A.V., Dmitriev, A.V., Bezhentsev, V.M., Lagunin, A.A., Filimonov, D.A., and Poroikov, V.V., SAR QSAR Environ. Res., 2017, vol. 28, no. 10, pp. 833–842. https://doi.org/10.1080/1062936X.2017.1399165
Rudik, A., Dmitriev, A., Lagunin, A., Filimonov, D., and Poroikov, V., Bioinformatics, 2015, vol. 31, no. 12, pp. 2046–2048. https://doi.org/10.1093/bioinformatics/btv087
Ivanov, S.M., Lagunin, A.A., Rudik, A.V., Filimonov, D.A., and Poroikov, V.V., J. Chem. Inf. Model., 2018, vol. 58, no. 1. https://doi.org/10.1021/acs.jcim.7b00568
Kuhn, M., Letunic, I., Jensen, L.J., and Bork, P., Nucleic Acids Res., 2016, vol. 44, no. D1, pp. D1075–D1079. https://doi.org/10.1093/nar/gkv1075
Chen, M., Bisgin, H., Tong, L., Hong, H., Fang, H., Borlak, J., and Tong, W., Biomarkers Med., 2014, vol. 8, no. 2, pp. 201–213. https://doi.org/10.2217/bmm.13.146
Fourches, D., Muratov, E., and Tropsha, A., Nat. Chem. Biol., 2015, vol. 11, no. 8, p. 535. https://doi.org/10.1038/nchembio.1881
URL: ftp://ftp.epa.gov/dsstoxftp/DSSTox_Archive_ 20150930/CPDBAS_DownloadFiles/.
Lagunin, A., Rudik, A., Druzhilovsky, D., Filimonov, D., and Poroikov, V., Bioinformatics, 2018, vol. 34, no. 4, pp. 710–712. https://doi.org/10.1093/bioinformatics/btx678
Berezovskaya, I.V., Pharm. Chem. J., 2003, vol. 37, no. 3, pp. 139–141.
Boelsterli, U.A., Toxicol. Appl. Pharmacol., 2003, vol. 192, no. 3, pp. 307–322.
Kalgutkar, A.S., Dalvi, D., Obach, R.S., and Smith, D.A., in Reactive Drug Metabolites, Mannhold, R., Kubinyi, H., and Folkers, G., Eds., Willey-VCH, 2012.
Funding
This work was supported by the Russian Science Foundation (project no. 14-15-00449).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This article does not contain any research involving humans or using animals as objects.
Additional information
Translated by A. Medvedev
Rights and permissions
About this article
Cite this article
Rudik, A.V., Dmitriev, A.V., Lagunin, A.A. et al. Computer-Aided Xenobiotic Toxicity Prediction Taking into Account their Metabolism in the Human Body. Biochem. Moscow Suppl. Ser. B 13, 228–236 (2019). https://doi.org/10.1134/S1990750819030065
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1990750819030065